Effects of dextranation on the pharmacokinetics of short peptides. A PET study on mEGF

Bioconjugate Chemistry

Volumn 10, Issue 6, 1999, Pages 938-946

  Zhao, Qinghai ^a   Tolmachev, Vladimir ^a   Carlsson, Jörgen ^a   Lundqvist, Hans ^a   Sundin, Johanna ^a,b   Janson, Jan Christer ^c,d   Sundin, Anders ^b  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c GE Healthcare Bio Sciences AB   (Sweden)

^d UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

POSITRON EMISSION TOMOGRAPHY; POSITRONS;

BIODISTRIBUTIONS; CIRCULATION TIME; EPIDERMAL GROWTH FACTORS; IN-VIVO; INTRAVENOUS ADMINISTRATION; MEASUREMENTS OF; NONCONJUGATED; REDUCTIVE AMINATION; RETENTION TIME; SPRAGUE-DAWLEY RATS;

DEXTRAN;

EID: 0033229967     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc990011l     Document Type: Article

References (43)

1. Cote, G. L., and Robyt, J. F. (1982) Isolation and partial characterization of an extracellular glucansucrase from Leuconostoc mesenteroides NRRL B-1355 that synthesizes an alternating (1 goes to 6), (1 goes to 3)-alpha-D-glucan. Carbohydr. Res. 101, 57-74.
2. Larm, O., Lindberg, B., and Svensson, S. (1971) Studies on the length of the side chains of the dextran elaborated by Leuconostoc mesenteroides NRRL B-512. Carbohydr. Res. 20, 39-48.
3. Steinmann, E., Duckert, F., and Gruber, U. F. (1975) The value of dextran 70 in the prevention of thromboembolism in general surgery, orthopedics, urology and gynecology. A review of the literature. Schweiz. Med. Wochenschr. 105, 1637-1649.
4. Atik, M. (1967) Dextran 40 and dextran 70. A review. Arch. Surg. 94, 664-672.
5. Dubick, M. A., and Wade, C. E. (1994) A review of the efficacy and safety of 7.5% NaCl/6% dextran 70 in experimental animals and in humans. J. Trauma. 36, 323-330.
6. Baudys, M., Letourneur, D., Liu, F., Mix, D., Jozefonvicz, J., and Kim S. W. (1998) Extending insulin action in vivo by conjugation to carboxymethyl dextran. Bioconjugate Chem. 9, 176-183.
7. Takakura, Y., Fujita, T., Hashida, M., Maeda, H., and Sezaki, H. (1989) Control of pharmaceutical properties of soybean trypsin inhibitor by conjugation with dextran. II: Biopharmaceutical and pharmacological properties. J. Pharm. Sci. 78, 219.
8. Sjostrom, A., Bue, P., Malmstrom, P. U., Nilsson, S., and Carlsson, J. (1997) Binding, internalization and degradation of EGF-dextran conjugates in two human bladder-cancer cell lines. Int. J. Cancer. 70, 383-389.
9. Lindstrom, A., and Carlsson, J. (1993) Penetration and binding of epidermal growth factor-dextran conjugates in spheroids of human glioma origin. Cancer Biother. 8, 145-158.
10. Gedda, L., Olsson, P., Ponten, J., and Carlsson, J. (1996) Development and in vitro studies of epidermal growth factor-dextran conjugates for boron neutron capture therapy. Bioconjugate Chem. 7, 584-591.
11. Carlsson, J., Gedda, L., Gronvik, C., Hartman, T., Lindstrom, A., Lindstrom, P., Lundqvist, H., Lovqvist, A., Malmqvist, J., and Olsson, P., et al. (1994) Strategy for boron neutron capture therapy against tumor cells with overexpression of the epidermal growth factor-receptor. Int. J. Radiat. Oncol. Biol. Phys. 30, 105-115.
12. Olsson, P., Lindstrom, A., and Carlsson, J. (1994) Internalization and excretion of epidermal growth factor-dextran-associated radioactivity in cultured human squamous-carcinoma cells. Int. J. Cancer. 56, 529-537.
13. Carpenter, G., and Cohen, S. (1990) Epidermal growth factor. J. Biol. Chem. 265, 7709-7712.
14. Libermann, T. A., Nusbaum, H. R., Razon, N., Kris, R., Lax, I., Soreq, H., Whittle, N., Waterfield, M. D., Ullrich, A., and Schlessinger, J. (1985) Amplification and overexpression of the EGF receptor gene in primary human glioblastomas. J. Cell. Sci. Suppl. 3, 161-172.
15. Messing, E. M., and Reznikoff, C. A. (1992) Epidermal growth factor and its receptor: markers of-and targets forchemoprevention of bladder cancer. J. Cell. Biochem. Suppl. 161, 56-62.
16. Sauter, G., Haley, J., Chew, K., Kerschmann, R., Moore, D., Carroll, P., Moch, H., Gudat, F., Mihatsch, M. J., and Waldman, F. (1994) Epidermal-growth-factor-receptor expression is associated with rapid tumor proliferation in bladder cancer. Int. J. Cancer 57, 508-514.
17. Filmus, J., Trent, J. M., Pollak, M. N., and Buick, R. N. (1987) Epidermal growth factor receptor gene-amplified MDA-468 breast cancer cell line and its nonamplified variants. Mol. Cell. Biol. 7, 251-257.
18. Hernandez Sotomayor, S. M., Arteaga, C. L., Soler, C., and Carpenter, G. (1993) Epidermal growth factor stimulates substrate-selective protein-tyrosine-phosphatase activity. Proc. Natl. Acad. Sci. U.S.A. 90, 7691-7695.
19. Burwen, S. J., Barker, M. E., Goldman, I. S., Hradek, G. T., Raper, S. E., and Jones, A. L. (1984) Transport of epidermal growth factor by rat liver: evidence for a nonlysosomal pathway. J. Cell Biol. 99, 1259-1265.
20. Jorgensen, P. E., Poulsen, S. S., and Nexo, E. (1988) Distribution of iv administered epidermal growth factor in the rat. Regul. Pept. 23, 161-169.
21. Mateo de Acosta, C., Justiz, E., Skoog, L., and Lage, A. (1989) Biodistribution of radioactive epidermal growth factor in normal and tumor bearing mice. Anticancer Res. 9, 87-92.
22. Yanai, S., Sugiyama, Y., Iga, T., Fuwa, T., and Hanano, M. (1990) Kinetic analysis of the downregulation of epidermal growth factor receptors in rats in vivo. Am. J. Physiol. 258, C593-598.
23. Scott Robson, S., Capala, J., Carlsson, J., Malmborg, P., and Lundqvist, H. (1991) Distribution and stability in the rat of a 76Br/125I-labeled polypeptide, epidermal growth factor. Int. J. Rad. Appl. Instrum. B 18, 241-246.
24. Fujita, T., Nishikawa, M., Tamaki, C., Takakura, Y., Hashida, M., and Sezaki, H. (1992) Targeted delivery of human recombinant superoxide dismutase by chemical modification with mono-and polysaccharide derivatives. J. Pharmacol. Exp. Ther. 263, 971-978.
25. Mikolajczyk, S. D., Meyer, D. L., Fagnani, R., Hagan, M. S., Law, K. L., and Starling, J. J. (1996) Dextran modification of a Fab′-β-lactamase conjugate modulated by variable pretreatment of Fab′ with amine-blocking reagents. Bioconjugate Chem. 7, 150-158.
26. Zhao, Q., Gottschalk, I., Carlsson, J., Arvidsson, L.-E., Oscarsson, S., Medin, A., Ersson, B., and Janson, J.-C. (1997) Preparation and Purification of an End to End coupled mEGF-dextran conjugate. Bioconjugate Chem. 8, 927-934.
27. 76Br by a low-energy cyclotron. Appl. Radiat. Isot. 49, 1537-1540.
28. Patlak, C., Blasberg, R., and Fenstermacher, J. (1983) Graphic evaluation of blood-to-brain transfer constants from multiple-time uptake data. J. Cerebr. Blood. Flow. Metab. 3, 1-7.
29. Carpenter, G., and Cohen, S. (1976) 125-I labeled human growth factor. J. Cell Biol. 71, 159-171.
30. Bergstrom, M., Litton, J., Eriksson, L., Bohm, C., and Blomqvist, G. (1982) Determination of object contour from projections for attenuation correction in cranial positron emission tomography. J. Comput. Assist. Tomogr. 6, 365-372.
31. Jorgensen, P. E., Rasmussen, T. N., Skov Olsen, P., Raaberg, L., Seier Poulsen, S., and Nexo, E. (1990) Renal uptake and excretion of epidermal growth factor from plasma in the rat. Regul. Pept. 28, 273-281.
32. Kim, D., Sugiyama, Y., Fuwa, T., Sakamatomo, S., Iga, T., and Hanano, M. (1989) Kinetic analysis of the elimination process of human epidermal growth factor (hEGF) in rats. Biochem. Pharm. 38, 241-249.
33. Renfrew, C. A., and Hubbard, A. L. (1991) Sequental Processing of epidermal growth factor in early and late endosomas of rat liver. J. Biol. Chem. 266, 4348-4356.
34. Cuartero-Plaza, A., Martinez-Miralles, E., Rossel, R., Vadell-Nadal, C., Farre., Magi., and Real., F. R. (1996) Radiolocalization of suamous lund carcinoma with 131I-labeled epidermal growth factor. Clin. Cancer Res. 2, 13-20.
35. Zhao, Q., Blomquist, E., Bolander, H., Gedda, L., Hartvig, P., Janson, J.-C., Lundqvist, H., Mellstedt, H., Nilsson, S., Nister, M., Sundin, A., Tolmachev, V., Westlin, J.-E., and Carlsson, J. (1998) Conjugate chemistry, iodination and cellular binding of mEGF-dextran-tyrosine: preclinical tests in preparation for clincal trials. Int. J. Mol. Med. 1, 693-702.
36. Behr, T. M., Goldenberg, D. M., and Becker, W. (1998) Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur. J. Nucl. Med. 25, 201-212.
37. Bernard, B. F., Krenning, E. P., Breeman, W. A., Rolleman, E. J., Bakker, W. H., Visser, T. J., Macke, H., and de Jong, M. J. (1997) D-lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake. J. Nucl. Med. 38, 1929-1933.
38. De Jong, M., Bakker, W. H., Breeman, W. A., Bernard, B. F., Hofland, L. J., Visser, T. J., Srinivasan, A., Schmidt, M., Behe, M., Macke, H. R., and Krenning, E. P. (1998) Preclinical comparison of [DTPAO] octreotide, [DTPA0, Tyr3] octreotide and [DOTA0, Tyr3] octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapy. Int. J. Cancer 7, 406-411.
39. Behr, T. M., Becker, W. S., Sharkey, R. M., Juweid, M. E., Dunn, R. M., Bair, H. J., Wolf, F. G., and Goldenberg, D. M. (1996) Reduction of renal uptake of monoclonal antibody fragments by amino acid infusion. J. Nucl. Med. 37, 829-833.
40. Tarburton, J. P., Halpern, S. E., Hagan, P. L., Sudora, E., Chen, A., Fridman, D. M., and Pfaff, A. E. (1990) Effect of acetylation on monoclonal antibody ZCE-025 Fab′: distribution in normal and tumor-bearing mice. J. Biol. Response Modif. 9, 221-230.
41. Zhao, Q., and Carlsson, J. (1997) In vitro characterization of an end-end coupled mEGF-dextran conjugate using a cultured human glioma cell line. Int. J. Oncol. 11, 1263-1269.
42. Heldin, C.-H., and Östman, A. (1996) Ligand-induced dimerization of growth factor receptors: variation on the theme. Cytokine Growth Factor Rev. 7, 3-10.
43. Kyriakos, R. J., Shih, L. B., Ong, G. L., Patel, K., Goldenberg, D. M., and Mattes, M. J. (1992) The fate of antibodies bound to the surface of tumor cells in vitro. Cancer Res 52, 835-842.